Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Aceragen, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the research and development of medications for rare and orphan diseases. The firm’s product portfolio includes ACG-801 and ACG-701, which targets Farber Disease, Melioidosis, and Cystic Fibrosis. The company was founded in 1989 and is headquartered in Exton, PA.
The company's experimental cancer drug flopped in a late-stage study.
Is there a light at the end of the tunnel?
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.